AusperBio Secures $37M Series A Funding

AusperBio recently announced the successful completion of its Series A funding round, securing up to $37 million. This financing was led by InnoPinnacle Fund, with significant contributions from Yuanbio Venture Capital, Hankang Capital, Qiming Venture Capital, Genesis Capital, and other prominent investors. The announcement has garnered considerable attention within the industry.

AusperBio is a trailblazing drug development company with operations in both the United States and China. It specializes in the research and development of first-in-class and best-in-class autonomous targeted delivery of small nucleic acid drugs. The company is renowned for its Med-OligoTM technology platform, which it fully owns and holds independent intellectual property rights over. This platform primarily targets the functional cure of chronic hepatitis B and the targeted therapy of liver diseases.

The funds raised from this round of financing will be allocated to advance the Phase II clinical trials for AusperBio's leading hepatitis B cure candidate, AHB-137. Additionally, the funds will support the exploration of combination treatment options and the optimization of manufacturing processes. The financing will also facilitate the expansion of AusperBio's other innovative product pipelines.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, expressed his enthusiasm for the successful funding round, stating, "The success of this financing once again demonstrates investors' recognition of our research results. We will step up clinical development of AHB-137 and hope that this potential cure will benefit patients around the world as soon as possible."

Dr. Yang Chengyong, co-founder and CSO of AusperBio, also acknowledged the support from investors, saying, "We would like to thank our investors for their support and trust. In the future, we will continue to leverage our strengths in oligonucleotide research and development and targeted delivery technology to promote more innovative therapies to benefit patients."

This major funding milestone will enable AusperBio to advance its mission of developing groundbreaking therapies for chronic illnesses. With the financial backing from industry-leading investors, the company is well-positioned to make significant strides in the field of targeted drug delivery and oligonucleotide-based therapies.